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At present, patients with advanced Parkinson’s disease (PD) are unsatisfactorily controlled by currently used anti-Parkinsonian
dopaminergic drugs. Various studies suggest that therapeutic strategies based on nondopaminergic drugs might be helpful in
PD. Zolpidem, an imidazopyridine widely used as sleep inducer, shows high affinity only for GABAA receptors containing the
𝛼-1 subunit and facilitates GABAergic neurotransmission through a positive allosteric modulation of GABAA receptors. Various
observations, although preliminary, consistently suggest that in PD patients zolpidem may induce beneficial (and sometimes
remarkable) effects on motor symptoms even after single doses and may also improve dyskinesias. Since a high density of zolpidem
binding sites is in the two main output structures of the basal ganglia which are abnormally overactive in PD (internal globus
pallidus, GPi, and substantia nigra pars reticulata, SNr), it was hypothesized that in PD patients zolpidem may induce through
GABAA receptors an inhibition of GPi and SNr (and, possibly, of the subthalamic nucleus also), resulting in an increased activity
of motor cortical areas (such as supplementary motor area), which may give rise to improvement of motor symptoms of PD.
Randomized clinical trials are needed in order to assess the efficacy, safety, and tolerability of zolpidem in treating motor symptoms
of PD.
1. Introduction
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder, with a prevalence of 0.3%
in the general population in industrialized countries and
a prevalence of 4% in elderly people aged over 80 years
[1]. The clinical manifestations of PD include motor symp-
toms (bradykinesia, rigidity, postural instability, and resting
tremor) and a variety of nonmotor symptoms, including
cognitive impairment, behavioural symptoms [2], sleep dis-
turbances, and olfactory and autonomic dysfunction.
At present, pharmacological treatment of motor symp-
toms of PD, mainly based on the administration of dopamin-
ergic drugs (levodopa, dopamine agonists) and other drugs
involved in levodopa metabolism (monoamine oxidase-B
inhibitors, COMT inhibitors), may induce beneficial effects
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on Parkinsonian motor symptoms only for some years
after the onset of such symptoms and becomes usually
less effective later in the disease course [3]. In late disease
stages, various complications usually arise in PD patients
treated by dopaminergic drugs, such as on-off fluctuations
of Parkinsonian symptoms and dyskinesias (involuntary
movements of the head, trunk, and upper or lower limbs).
On the whole, at present, most patients with advanced PD are
unsatisfactorily controlled by the currently most widely used
anti-Parkinsonian drugs.
In the last fifteen years, the most significant advances
in the treatment of PD were represented by neurosurgical
procedures aimed at modulating the activity of specific brain
structures, such as deep brain stimulation (DBS) of the inter-
nal globus pallidus (GPi) andDBS of the subthalamic nucleus
(STN), which may induce remarkable beneficial effects in
PD patients [4], even after more than 10 years from the
neurosurgical intervention [5]. Preliminary studies suggest
that neurosurgical procedures alternative to DBS, such as
extradural stimulation of the motor cortex, are definitely less
effective than DBS of the STN or GPi, although extradural
stimulation of the motor cortex may induce slight beneficial
effects on Parkinsonian motor symptoms, including axial
motor symptoms which are usually poorly responsive to drug
treatment [6, 7].
It is well established that neuropathological processes
underlying PD involve not only dopaminergic systems, but
also noradrenergic, serotonergic, glutamatergic, and cholin-
ergic systems in several brain structures. So far, a number of
nondopaminergic drugs have been available for the treatment
of motor symptoms of PD [8], while other nondopaminergic
drugs are still under investigation. Among anti-Parkinsonian
drugs with pharmacological effects on nondopaminergic
systems, adenosine A2A receptor antagonists, safinamide
(an agent inhibiting both glutamate release and monoamine
oxidase-B), and the antiepileptic agent zonisamide have
been proposed as add-on drugs which may extend the
duration of effects of levodopa. To reduce levodopa-induced
dyskinesias, antiglutamatergic drugs, such as amantadine (a
nonselective N-methyl D-aspartate antagonist) and antago-
nists of metabotropic glutamate receptor (mGluR
5
), might
be helpful in PD patients. As regards drugs with pharma-
cological effects on serotonergic and noradrenergic systems,
5-HT2A/2C antagonists (such as the atypical antipsychotic
clozapine) and 𝛼2-adrenergic receptor antagonist (such as
fipamezole) may reduce dyskinesias in PD patients. As to
nondopaminergic drugs which can be used in PD patients for
the treatment of tremor, various options can be considered,
including anticholinergic drugs (muscarinic M4 cholinergic
antagonists), 𝛽-adrenergic antagonists (such as propranolol),
5-HT2A antagonists, and drugs with pharmacological effects
on both serotonergic and cholinergic systems (such as cloza-
pine and the antidepressant mirtazapine). It has been pointed
out that while dopaminergic drugs still remain the most
effective option to treat motor symptoms in PD, alternative
therapeutic strategies based on the use of nondopaminergic
drugs in PD are currently needed to improve symptoms that
are (or become) poorly responsive to dopaminergic drugs [8].
2. Potential Beneficial Effects of Zolpidem,
a Positive Allosteric Modulator of GABAA
Receptors, on the Motor Symptoms of PD
In the late 1980s, some opinion leaders in the field of
movement disorders [9] had suggested that drugs that may
specifically enhance GABAergic neurotransmission may be
potentially helpful in the treatment of PD, but at that
time there was scanty evidence supporting this intriguing
hypothesis. In particular, a pilot study had suggested that
GABA agonists such as progabide [10] might be helpful
in the treatment of motor symptoms of patients with PD,
in agreement with an experimental study in rats showing
the effects of progabide [11] on motor function (turning
behaviour) and with previous postmortem findings showing
abnormalities in the GABAergic systems of the brain of
patients with Parkinson’s disease [12].
Zolpidem is an imidazopyridine drug with short half-
life, which has been widely used for more than two decades
for the treatment of insomnia. Both zolpidem and ben-
zodiazepines (BZ) exert their pharmacological effects by
facilitating GABAergic neurotransmission through a pos-
itive allosteric modulation of GABAA receptors. GABAA
receptors, which are the major inhibitory neurotransmitter
receptors in the brain, are heteropentamers and are classified
according to their𝛼 subunits. InGABAA receptors containing
specific isoforms of 𝛼 subunits (𝛼1, 𝛼2, 𝛼3, and 𝛼5), there
is a binding site for BZ and zolpidem in the 𝛼 subunit
[13]. BZ bind relatively unselectively to several subtypes of
GABAA receptors, namely, those containing the 𝛼1, 𝛼2, 𝛼3,
or 𝛼5 subunits. Unlike BZ, zolpidem is an agonist with
high affinity only for GABAA receptors containing the 𝛼-1
subunit [14].The interaction of zolpidemwith the BZ binding
site of GABAA receptors (particularly, of GABAA receptors
containing the𝛼-1 subunit, given the high affinity of zolpidem
for such GABAA receptor subtype) results in facilitation of
GABAergic neurotransmission, particularly in neurons with
GABAA receptors containing the 𝛼-1 subunit. It has been
recently suggested that, according to pharmacological data
from both rodents and nonhuman primates, among drugs
currently available for clinicians, zolpidem has a peculiar
pharmacological profile, which differentiates zolpidem from
BZ [15]. Some studies have previously suggested that there is
a high density of zolpidem binding sites in the GPi and in the
substantia nigra pars reticulata (SNr), which are the output
structures of the basal ganglia [16, 17].
In the mid-1990s, Daniele and coworkers observed a
61-year-old woman affected by juvenile-onset PD in an
advanced disease stage after a 25-year clinical history, who
received at bedtime an oral immediate-release formulation of
zolpidem for insomnia [18]. Surprisingly, 45 to 60 minutes
after the assumption of the first 10mg dose of zolpidem
as sleep inducer, this patient showed no drowsiness but a
remarkable improvement of Parkinsonian motor symptoms
(akinesia, rigidity, and resting tremor). In this woman, the
motor improvement induced by a single 10mg dose of zolpi-
dem immediate-release was comparable to the improvement
observed after the administration of levodopa/carbidopa,
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while no beneficial effect on her Parkinsonian motor symp-
toms was observed when she assumed other hypnotic drugs
(triazolam and zopiclone). This patient with advanced PD
assumed zolpidem chronically (10mg four times daily) for
more than 5 years, with no side effects and persistent bene-
ficial effects on Parkinsonian motor symptoms over time.
Following such serendipitous observation, a pilot study
(double-blind, placebo-controlled crossover) was carried out
in ten patients with a clinical diagnosis of PD [18], with
a mean disease duration of 9.2 years and a mean Hoen
and Yahr score of 2.9 years. Since in the first serendipitous
observation even a single 10mg dose of zolpidem showed
beneficial effects on Parkinsonian motor symptoms about
one hour after the drug administration, in such pilot study
PD patients were given in randomized order a 10mg fixed
dose of immediate-release zolpidem and placebo in two
different days, after withholding of all anti-Parkinsonian
medication 12 hours before motor assessment. PD patients
were assessed by means of the motor examination part (part
III) of the Unified Parkinson’s Disease Rating Scale (UPDRS-
III) before (baseline) and one hour after the administration
of zolpidem or placebo. In each individual PD patient, a
positive response was defined as a decrease of more than 20%
of the UPDRS-III score at baseline. In this pilot study, the
administration of a single 10mg fixed dose of immediate-
release zolpidem, unlike placebo, induced in the overall group
of ten PD patients a statistically significant improvement of
Parkinsonian motor symptoms, with a 18% mean reduction
of UPDRS-III scores from baseline. Six out of 10 PD patients
could be defined as responders to a single 10mg dose of
zolpidem and showed on average a 30% improvement of
motor symptoms, ranging from 21% to 59% in different
individuals affected by PD. In PD patients who resulted in
being responders to zolpidem, such improvement (which
appeared 45–60minutes after the administration of zolpidem
and lasted about 2–4 hours) mainly involved facial expres-
sion, rigidity, akinesia/bradykinesia, posture, and gait. In this
group of 10 PD patients, in those patients who presented
resting tremor, the administration of a single 10mg dose
of zolpidem improved also resting tremor, although this
finding was not mentioned among the results reported by
Daniele and coworkers [18]. Interestingly, the 6 patients who
resulted in being responders to zolpidem included 3 out of
the 4 most severely affected PD patients and 3 out of the 6
less severely affected PD patients, suggesting the hypothesis
that beneficial effects of a single 10mg dose of immediate-
release zolpidem on Parkinsonian motor symptoms may
perhaps be more likely observed in PD patients with more
severe motor symptoms. In this pilot study, the only adverse
effect observed after the administration of a 10mg single
dose of immediate-release zolpidem was drowsiness, which
occurred in 4 out of 10 PD patients and was severe in
2 patients, moderate in one patient, and mild in another
patient. Interestingly, drowsiness was observed only in one
out of the 4 most severely affected patients and 3 out of the
6 less severely affected patients, suggesting that after a single
10mg dose of immediate-release zolpidem the occurrence of
drowsiness may be less likely observed in PD patients with
more severe motor symptoms. Despite the beneficial effects
on Parkinsonian motor symptoms in 6 out of 10 PD patients,
a single 10mg dose of zolpidem did not induce dyskinesias in
any patient, even in 3 PD patients who had showed levodopa-
induced dyskinesias.
In 2000, Růžička and coworkers [19] reported a 45-
year-old woman with 12-year history of PD. Eight months
after levodopa was started in 1992 and 5 years after disease
onset, the patient developed choreic dyskinesias of the right
hand. Later on, dyskinesias became generalized and were
present most of the time. A number of treatment strate-
gies (controlled-release levodopa, addition to levodopa of
bromocriptine, terguride, and tiapride) failed to alleviate such
dyskinesias. In 1994, she was given zolpidem for insomnia,
and 30 minutes after 2.5 to 5mg of zolpidem, her dyskinesias
substantially diminished or disappeared for 2 hours, without
any drowsiness. In 1997, when motor fluctuations developed,
she also noticed an improvement of motor function, if the
dose of zolpidem was taken in the “off” state. This PD
patient increased the dosage of zolpidem up to 30mg per day
(divided into 6 doses of 5mg), with a persistent antidyskinetic
effect “on” levodopa and improved motricity (especially gait
initiation) in the “off” state, without daytime somnolence.
After more than 3 years of chronic treatment with zolpidem,
the single doses of zolpidem had not been substantially
increased. This observation suggested the potential benefits
of the chronic administration of zolpidem not only on
Parkinsonianmotor symptoms, but also on dyskinesias in late
stages of PD.
In 2004, at the 8th International Congress of Parkin-
son’s Disease and Movement Disorders organized by the
Movement Disorders Society, Tagaris and coworkers [20]
presented preliminary data on some remarkable beneficial
effects induced by the administration of zolpidem on motor
symptoms of patients with advanced PD. As far as we are
aware, such interesting data have been reported so far only
as an abstract of such congress. In an initial study on a
group of 14 PD patients receiving zolpidem for insom-
nia ([20]; Tagaris, personal communication, 2004), Tagaris
and coworkers investigated a subgroup of 5 PD patients,
who self-reported robust beneficial effects on Parkinsonian
motor symptoms induced by the assumption of zolpidem
for insomnia. In this first subgroup of 5 PD patients, who
also showed frequent and severe dyskinesias, Parkinsonian
motor symptoms were assessed by means of the UPDRS-
III before and after the administration of single doses of
levodopa and single 5 or 10mg doses of immediate-release
zolpidem. In this subgroup of 5 PDpatients, zolpidem (unlike
the BZ temazepam) induced a dramatic improvement of
Parkinsonian motor symptoms, comparable to the improve-
ment induced by levodopa. Accordingly, in this subgroup
of 5 PD patients, zolpidem was administered chronically, in
daily doses of 30mg or more. One of such PD patients out
of five showed a tendency to abuse zolpidem and assumed
zolpidem almost every 2 hours. Interestingly, 2 out of 5
PD patients reported an improvement of levodopa-induced
dyskinesias if levodopa was administered in association with
zolpidem, while no patient reported dyskinesias after the
administration of zolpidem. In a second study (Tagaris,
personal communication, 2004 [20]), a single oral dose of
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immediate-release zolpidem 5mg or flunitrazepam 1mg was
administered to another group of 10 patients with advanced
PD, who had never received zolpidem before. If no anti-
Parkinsonian effect and no sleepiness were detected after
the administration of a 5mg single dose of zolpidem (as
observed in 5 out of 10 PD patients), the single dose of
zolpidemwas then increased to 10mg. Soon (30–45 minutes)
after the administration of a single oral dose of zolpidem, a
significant motor improvement (decrease of more than 20%
in the baseline score of UPDRS) was observed in 7 out of 10
patients with advanced PD. In these patients, no improve-
ment of Parkinsonian motor symptoms was observed after
the administration of the BZ flunitrazepam. In this latter
study, a slight somnolence was observed in 4 out of those 5
PD patients who were given a single 10mg dose of zolpidem
and in 2 out of those 5 PD patients who were given a
single 5mg dose of zolpidem, while sleepiness was observed
only in 1 PD patient after a single 5mg dose of zolpidem.
These preliminary observations showed that single oral doses
of zolpidem as well as chronic administration of zolpidem
may improve Parkinsonian motor symptoms in patients with
advanced PD, suggesting that the anti-Parkinsonian effects of
zolpidem may perhaps be more pronounced in PD patients
with dyskinesias.
The hypothesis that the administration of zolpidem is
more likely to improve Parkinsonian motor symptoms in
patients with advanced PDwas supported by a clinical obser-
vation reported by Chen and coworkers [21] in a 53-year-
old patient with advanced PD, who underwent unilateral
pallidotomy, unilateral thalamotomy, and bilateral DBS of the
STN. In this PD patient, the administration of a single 10mg
dose of zolpidem rapidly induced a remarkable amelioration
of Parkinsonian motor symptoms (akinesia, dystonia, and
dyskinesias), with a 27% improvement on the UPDRS-III
scale and no significant somnolence with a 10mg dose of
zolpidem. After the administration of a lower dosage of
zolpidem (5mg), there was an amelioration of dystonia and
dyskinesias, in the absence of a satisfactory improvement
of other Parkinsonian motor symptoms. In this patient,
zolpidem was chronically administered at a daily dosage of
25mg (5mg three times a day and 10mg before sleeping).
This observation suggests that, in patients with advanced
PD, such as patients who underwent DBS of the STN and
more invasive neurosurgical interventions (pallidotomy and
thalamotomy), zolpidem may improve various Parkinsonian
motor symptoms, including dystonia and dyskinesias, possi-
bly at relatively lower doses.
In 2010, at the 14th International Congress of Parkin-
son’s Disease and Movement Disorders organized by the
Movement Disorders Society, Abaroa and coworkers [22]
described three patients affected by PD with motor fluctu-
ations and dyskinesias. The first patient was a 50-year-old
man, with a 3-year disease duration, in stage 3 on the Hoehn
and Yahr (HY) scale. He showed wearing off and dyskinesias,
with foot dystonia and severe pain in lower limbs in off state.
The second patient (a 76-year-old man, with a 12-year disease
duration, in stage 3 on the HY scale) showed wearing off
and severe off states with akinesia, foot and oromandibular
dystonia, and pain in lower limbs. The third patient (a 61-
year-old woman, with an 8-year disease duration, in stage
3 on the HY scale) showed wearing off, dyskinesias, severe
trunk, and cervical dystonia associated with pain in lower
limbs in off state. All 3 patients were assessed by means of
the UPDRS-III before and after the oral administration of
a single 7.5mg dose of zolpidem. About 15–20 minutes after
the oral administration of such single dose of zolpidem, in all
patients dystonia disappeared and, for about 1-2 hours, there
was a remarkable improvement of pain, dysphagia, and other
Parkinsonianmotors symptoms assessed byUPDRS-III (with
a reduction of 30% or more of UPDRS-III scores). None of
the 3 PD patients showed drowsiness after the assumption
of zolpidem. It was briefly mentioned [22] that in two PD
patients the remarkable improvement of UPDRS-III scores
obtained after the administration of a single dose of zolpidem
was comparable to the improvement obtained with levodopa,
while in a third patient the improvement ofUPDRS-III scores
obtained after the administration of a 7.5mg dose of zolpidem
was even greater than the motor improvement obtained with
levodopa. This report suggests that zolpidem may improve
Parkinsonianmotor symptoms (including dystonia and dysk-
inesias) in patients with fluctuating PD, such as patients with
mild to moderate bilateral disease who have complications
associated with long-term levodopa treatment.
In 2012, Huang and coworkers [23] reported a 61-year-old
housewife with PD and a 12-year disease duration, with rest
tremor of right limbs as presenting symptom.The patient was
referred to hospital in March 2009 because of both the short-
ening of beneficial effects of pharmacological treatment in the
preceding 3 years and the appearance of on-phase dyskinesias
in the preceding 2 years. In June 2009, she underwent bilateral
DBS of STN. The day after the neurosurgical intervention,
the patient started to show “fluctuating spells of mental
confusion (inertia and confusion with incoherent speech
and fearing of being killed),” which persisted over time.
In July 2009, soon after the administration of zolpidem for
insomnia, the patient showed for few hours an improvement
of Parkinsonian motor symptoms (with approximately a 25%
improvement on the UPDRS-III scale) and an amelioration
of behavioural symptoms: “she could chat normally with her
caregiver and walk with assistance after taking zolpidem.”
In keeping with the behavioural improvement observed
after the administration of zolpidem, the total score on
the Neuropsychiatric Inventory (which was administered to
assess her behavioural symptoms) decreased from 56 to 30.
Accordingly, zolpidem was administered to the patient at a
dosage of 10mg three times per day. In this patient, positron
emission tomography with 18FF-fluorodeoxyglucose showed
a reduction of metabolism in the right frontal and parietal
cortex and in caudate nucleus, which improved after the
administration of zolpidem.
In recent years, neurophysiological studies aimed at
registering cerebral electrical activity in PD showed that in
patients with PD a pathological increase of beta activity
(15–35Hz) oscillations may occur in various brain struc-
tures, such as the STN and the cerebral cortex [24, 25].
A relationship between such pathologically increased beta
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activity in PD patients and severity of Parkinsonian motor
symptoms has been hypothesized, since a reduction of such
pathologically increased beta activity may be observed in PD
patients after improvement of Parkinsonianmotor symptoms
following either pharmacological treatment with levodopa
[26] or DBS of the STN [27]. It has been also suggested that
beta activity oscillations in the primary motor cortex may
be modulated by GABAergic mechanisms and that drugs
modulating GABAA receptors such as diazepam may reduce
the frequency of beta activity oscillations [28].
In a recent study, Hall and coworkers [29] investigated a
group of 9 PD patients in early disease stages (with unilateral
Parkinsonian motor symptoms only) and a group of 9 age-
matched healthy controls. Participants of both groups under-
went two magnetoencephalography (MEG) recording ses-
sions, at baseline and after the administration of a single low
(namely, subsedative) oral dose of zolpidem (0.05mg/kg). At
baseline, as shown in previous studies, PD patients showed
an increase of beta power in the primary motor cortex (M1),
which was greater in M1 area contralateral to the body side
affected by Parkinsonian motor symptoms, as compared to
M1 area ipsilateral to the body side affected by Parkinsonian
motor symptoms. After the administration of a single low
(individually adjusted, according to body weight) oral dose
of zolpidem, all PD patients showed a remarkable and
statistically significant improvement of Parkinsonian motor
symptoms (with approximately a 50%mean reduction of total
score onUPDRS-III), with a statistically significant ameliora-
tion ofmost items ofUPDRS-III (resting and postural tremor,
rigidity of upper and lower limb, finger tapping, hand move-
ments, rapid alternatingmovements of hands, postural stabil-
ity, and bradykinesia). Moreover, after the administration of
a single low oral dose of zolpidem in PD patients, beta power
was significantly reduced in contralateral M1 area, while it
was significantly increased in ipsilateral M1 area, resulting
in a hemispheric beta power ratio between the right and left
M1 areas that approached parity. Furthermore, in PD patients
there was highly significant correlation between the changes
in hemispheric beta power ratio in M1 areas induced by
zolpidem (significant reduction of beta power in contralateral
M1 area and significant increase of beta power in ipsilateral
M1 area, resulting in a hemispheric beta power ratio between
the right and left M1 areas that approached parity) and the
improvement induced by zolpidem on Parkinsonian motor
symptoms as assessed by scores on UPDRS-III scale. These
findings show that in PD patients the oral administration
of zolpidem in low doses may result in an improvement
of Parkinsonian motor symptoms, which is associated with
both a reduction of beta power in contralateral M1 area
and an increase of beta power in ipsilateral M1 area, thus
rebalancing the dynamic range of M1 network oscillations
betweenM1 areas of the two cerebral hemispheres [29]. From
a clinical viewpoint, this study suggests that low doses of
zolpidemmay improve Parkinsonianmotor symptoms also in
PD patients in early disease stages. It has been hypothesized
that zolpidem may markedly reduce the synchronous power
of pathological oscillations in brain structures in which a
pathologically increased beta power can be detected, namely,
that zolpidem may desynchronize such pathological activity,
with subsequent improvement of motor function [30].
In conclusion, the limited evidence available so far
suggests that, after the administration of single oral doses
mostly ranging between 2.5mg and 10mg, a response (motor
improvement) to immediate-release formulations of zolpi-
dem might be more likely in PD patients with the following
clinical features: (a) patients with moderate to severe PD
[18], including patients with advanced PD [18, 20, 21, 23]; (b)
PD patients with dyskinesias [19–22] and motor fluctuations
[19, 22]. Such preliminary evidence, however, does not rule
out the possibility that even patients with mild PD may
respond to zolpidem, as it has been shown that PD patients
in early disease stages [22, 29] may show an improvement
of Parkinsonian motor symptoms after the administration of
low (0.05mg/kg) single oral doses of zolpidem (e.g., a 3.5mg
dose for a patient who weighs 70 kg).
3. Possible Mechanisms Underlying the
Potential Beneficial Effects of Zolpidem
on Parkinsonian Motor Symptoms
It is well established that dopaminergic depletion resulting
from neurodegenerative processes affecting dopaminergic
neurons in the SN pars compacta gives rise in PD patients
to overactivity of the two main inhibitory output structures
of the basal ganglia, namely, the GPi and the SNr. The over-
activity of such two inhibitory output GABAergic structures
in the basal ganglia gives rise to decreased activity in specific
thalamic nuclei and, in turn, in reduced activity of motor
cortical areas (such as supplementarymotor area), whichmay
result in motor symptoms of PD (Figure 1(b)).
In order to explain the quite surprising potential benefi-
cial effects on Parkinsonian motor symptoms even of single
doses of the hypnotic drug zolpidem observed in their pilot
study, Daniele and coworkers [18] proposed a hypothesis
about the possible mechanisms underlying these effects.
Such hypothesis is based on the fact that zolpidem, unlike
benzodiazepines, is an agonist with high affinity for GABAA
receptors containing the 𝛼-1 subunit [14], previously named
GABAA-BZ1 receptors, and therefore facilitates GABAergic
neurotransmission in brain structures which preferentially
contain GABAA receptors with the 𝛼-1 subunit. Since some
studies [16, 17] had suggested that there is a high density
of zolpidem binding sites in the GPi and in the SNr (the
two main output structures of the basal ganglia, which are
abnormally overactive in PD), it was hypothesized that in
PD patients zolpidemmay induce through GABAA receptors
a selective inhibition of such two overactive and inhibitory
GABAergic structures (the GPi and the SNr), resulting in
turn in an increased activity of motor cortical areas (such as
supplementary motor area), which may underlie the possible
improvement of Parkinsonianmotor symptomswhich can be
observed after the administration of zolpidem (Figure 1(c)) in
PD [18] and other Parkinsonian syndromes [31]. According to
this hypothesis, it was also speculated that the administration



































(c) Parkinson’s disease + zolpidem
Figure 1: Schematic representations of the activity of the cortical-basal ganglia loops, showing the direct (D) and indirect (I) circuits in
normal subjects (a), patients with Parkinson’s disease/Parkinsonism (b), and patients with Parkinson’s disease treated with zolpidem (c). In
PD [18], zolpidem may induce, through GABAA receptors containing the 𝛼1 subunit, a selective inhibition of the GPi and the SNr (the two
main inhibitory GABAergic output structures of the basal ganglia), which are overactive in PD (b) and show binding sites for zolpidem (c).
The inhibition of the GPi and the SNr directly induced by zolpidem may result in an increased activity of some motor cortical areas (such as
supplementarymotor area), whichmay underlie the possible improvement of Parkinsonianmotor symptoms which can be observed after the
administration of zolpidem. Although binding sites for zolpidem in the STN are not displayed in (c), the STNwas found to have binding sites
for zolpidem [36] andmight be reasonably considered an additional target for zolpidem in PDpatients. In PD, zolpidemmight inhibit the STN
as well, giving rise to decreased excitatory inputs from the STN to the GPi and SNr, resulting in a further mechanism leading to a decreased
activity of the GPi and SNr, indirectly induced by zolpidem through its inhibition of the STN. White arrows = excitatory connections; black
arrows = inhibitory connections.
This hypothesis has been subsequently supported by
experimental studies in rats [32, 33] and has been quoted in
several publications as a plausible explanation for the possible
anti-Parkinsonian effects of zolpidem in patients with PD and
other Parkinsonian syndromes [19–22, 31, 34, 35].
Chen and coworkers [32] investigated the in vitro and in
vivo effects of zolpidem on the globus pallidus (GP) in rats.
In their experimental study on in vitro slices of the GP in
rats, a single 100 nM dose of zolpidem enhanced the action of
GABA on postsynaptic GABAA receptors and prolonged the
duration of inhibitory postsynaptic currents recorded from
neurons of theGP.Moreover, in a study aimed at investigating
the effects of zolpidem in vivo on the GP in rats [32], when a
single dose of zolpidemwas acutelymicroinjected into theGP
unilaterally, a change in motor behaviour, namely, a robust
ipsilateral rotation (turning behaviour), was observed in the
behaving rats. Chen and coworkers [32] suggested that this
motor effect of zolpidem in vivo was due to the inhibition of
the activity of neurons of the GP induced by zolpidem. All
such effects of zolpidem, in vitro and in vivo, were sensitive
to the benzodiazepine antagonist flumazenil. These findings
on the in vitro and in vivo effects of zolpidem on the GP
in rats provided experimental support to the hypothesis of
a GP-mediated mechanism of the anti-Parkinson effects of
zolpidem in PD and suggested the need of further investi-
gations aimed at assessing the potential beneficial effects of
zolpidem in the treatment ofmovement disorders originating
from dysfunction of the basal ganglia.
Zhang and coworkers [33] investigated in vitro and in vivo
the effects of zolpidem on the SNr in rats. In in vitro slices
of the SNr, superfusion of zolpidem at 100 nM/L induced a
GABAergic inhibition of the SNr by activating postsynaptic
GABAA receptors and prolonged the duration of inhibitory
postsynaptic currents recorded from neurons of SNr. In an
experimental study on the effects of zolpidem in vivo on
the SNr, it was observed that a unilateral microinjection of
zolpidem into the SNr caused a change in motor behaviour,
namely, a robust contralateral rotation in the behaving rats.
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All such effects of zolpidem, in vitro and in vivo, were sensitive
to the BZ antagonist flumazenil.These findings on the in vitro
and in vivo effects of zolpidem on the SNr provided experi-
mental evidence about a possible SNr-mediated mechanism
of the anti-Parkinson effects of zolpidem in PD and further
supported the idea of a potential role of zolpidem in the
treatment of movement disorders arising from dysfunction
of the basal ganglia.
In conclusion, the two studies mentioned above [32,
33] provided an experimental support to the hypothesis of
Daniele and coworkers [18], who suggested that the poten-
tial beneficial effects of zolpidem on the motor symptoms
of PD patients may fundamentally arise from a selective
pharmacological inhibition, induced by zolpidem through
GABAA receptors in GPi and SNr (Figure 1(c)), of such
overactive inhibitory structures (GPi and SNr), resulting in
an increased activity of specific thalamic nuclei and, in turn,
in an increased activity of specific motor cortical areas (such
as supplementary motor area), which may give rise to an
improvement of Parkinsonian motor symptoms.
Further data about the possible mechanisms which may
underlie the potential anti-Parkinsonian effects of zolpidem
were provided by an additional experimental study in rats
[36], suggesting that zolpidem may induce beneficial effects
on themotor symptoms of patients with PD also by inhibiting
at least another subcortical nucleus overactive in PD (besides
GPi and SNr), namely, the STN.Chen and coworkers [36] car-
ried out an in vitro and in vivo study on the effects of zolpidem
on the STN, a brain structure which also shows a high density
of zolpidem binding sites [17] and plays a key role in the
indirect pathway of the basal ganglia circuits. In the in vitro
study [36], whole-cell patch clamp recordings were used to
investigate the modulation of zolpidem on GABAA receptor-
mediated inhibitory synaptic currents in the STN. Zolpidem
at a 100 nM dose significantly prolonged the decay time and
rise time of miniature inhibitory postsynaptic currents in
the STN, with no effect on the amplitude and frequency.
At a high concentration of 1 𝜇M, zolpidem significantly
increased the decay time, rise time, amplitude, and frequency
ofminiature inhibitory postsynaptic currents in the STN.The
BZ antagonist flumazenil could completely block the effects
induced by zolpidem, confirming that the effects of zolpidem
are mediated by the BZ recognition site. In an in vivo study
[36], a unilateral microinjection of zolpidem into the STN
induced a significant contralateral rotation in the behaving
rats. These results about the in vitro and in vivo effects of
zolpidem on the STN provided experimental support to the
hypothesis of a possible STN-mediated mechanism of the
anti-Parkinson effects of zolpidem in PD and were in keeping
with previous suggestions about a potential role of zolpidem
in the treatment of movement disorders associated with a
dysfunction of the basal ganglia. According to these latter
findings, we might hypothesize that the administration of
zolpidem, to some extent and perhaps in a subset of PD
patients, could maybe provide a pharmacological equivalent
also of neurosurgical procedures aimed at inhibiting the
overactivity of the STN in patients with PD, such as DBS of
the STN.
In conclusion, current available evidence suggests that
zolpidem may induce a selective inhibition not only of the
two output structures of the basal ganglia (GPi and SNr)
which are overactive in PD [18], but also of an additional
overactive structure in the basal ganglia pathways such as the
STN, which might be reasonably considered an additional
target for zolpidem, although it is not reported in Figure 1(c)
as a target structure for zolpidem. Accordingly, zolpidemmay
induce a selective inhibition of various overactive structures
in PD (GPi, SNr, and STN), which may be analogous to the
functional inactivation of the STN or the GPi induced by
DBS.
However, it is not possible to rule out the possibility
that further brain structures containing GABAA receptors,
including specific neuron populations of some areas of the
cerebral cortex, might be involved in the potential beneficial
effects of zolpidem in improving Parkinsonian motor symp-
toms.
In a recent study on a mouse model of PD [37], it was
shown that dopamine depletion induced by the neurotoxin
MPTP may give rise (through D1 and D2 receptors) to
marked changes in synaptic dynamics of pyramidal neurons
in M1, which receive direct dopaminergic projections from
the ventral tegmental area and the substantia nigra pars
compacta. In such MPTP-treated mice, the synaptic remod-
eling in M1, induced through D1 and D2 receptors (with D1
receptor signaling linked to dendritic spine elimination and
D2 receptor signaling linked to dendritic spine formation),
gives rise to a net loss of stable dendritic spines in pyramidal
cortical neurons of layer V and results in abnormal structural
and functional plasticity in the motor cortex. Likewise, it
was hypothesized that in patients with PD an abnormal
synaptic plasticity in the motor cortex may contribute to the
development of motor impairment (including impairment
of motor learning) and that treatment strategies aimed at
modifying such abnormal synaptic plasticity in the motor
cortex may have beneficial effects in PD patients [37].
Recently, an experimental study in rats [38] using an in
vitro brain slice model of neuronal oscillatory activity and
a kinetic model of GABAA receptor dynamics showed that
zolpidem in low concentrations may reduce beta power in
M1 cortical area, possibly through its action on inhibitory
interneurons of the cortical area M1. Likewise, it has been
also hypothesized [38] that in patients with PD low doses
of zolpidem, through its possible effects on fast spiking
inhibitory interneurons in M1 cortical area, may induce an
increased tonic inhibition of such cortical interneurons in
M1, which may give rise to an improvement of Parkinsonian
motor symptoms.
4. Possible Mechanisms Underlying the
Individual Variability of the Potential
Effects of Zolpidem in Patients with PD
Current clinical evidence, although limited, suggests that, in
those PDpatientswho showan improvement of Parkinsonian
motor symptoms after the administration of zolpidem, the
optimal dose of zolpidem may remarkably vary in different
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individuals. Similarly, the dosage of zolpidem which may
induce sedation or drowsiness seems also to markedly vary
in different PD patients, since some PD patients do not
experience drowsiness even with relatively higher doses of
zolpidem, while other PD patients do easily experience
drowsiness after taking relatively low doses of zolpidem. On
the whole, provided that there is apparently some individual
variability of the effects of zolpidem in different patients
affected by PD, the scanty available evidence suggests that in
PD patients in more advanced disease stages (and presenting
with more severe Parkinsonian motor symptoms) a single
dose of zolpidem of about 10mg (the standard dose for
insomnia) ismore likely to induce an improvement of Parkin-
sonian motor symptoms, in comparison with PD patients in
early stages and presenting with mild Parkinsonian motor
symptoms [18–22]. Likewise, PD patients in more advanced
disease stages and presenting with more severe Parkinsonian
motor symptoms seem on average to better tolerate doses
of about 7.5 or 10mg of zolpidem (namely, they show less
frequently sedation or drowsiness after the assumption of
such doses of zolpidem), as compared with PD patients in
early stages and presenting with mild Parkinsonian motor
symptoms [18–22].
It is not easy to understand why, at least in a subset of
PD patients, zolpidem does not induce drowsiness at dosages
which usually induce sleep in normal subjects and why there
is a remarkable individual variability in the occurrence of
an improvement of Parkinsonian motor symptoms after the
administration of zolpidem. In the attempt to give a possible
answer to such intriguing questions, it is helpful to take
into account some prompts deriving from few experimental
studies.
In animal models of Parkinsonism, after lesions of the
substantia nigra pars compacta (SNc) or lesion of striatal
nuclei, an increase of the density of GABAA receptors con-
taining the binding sites for BZ (previously named GABAA-
BZ receptors) may occur in specific structures within the
basal ganglia. In cynomolgus monkeys with experimental
Parkinsonism induced by the injection ofMPTP, an increased
density ofGABAA-BZ receptorswas observed in theGPi [39].
After unilateral 6-hydroxydopamine lesions of the medial
forebrain bundle in the rat, an increased number of GABA
and BZ binding sites were detected in the SNr and in the
entopenduncular nucleus, which is the rodent counterpart
of the GPi [40]. Moreover, it has been suggested that in PD
the underactivity of GABAergic neurons of the putamen and
caudate projecting through the direct pathway to GPi and
SNr may result in compensatory upregulation of GABAA
receptors [39] in deafferented brain structures, namely, the
GPi and SNr (Figure 2(b)).
In normal subjects, homeostatic mechanisms in the STN
[41] may regulate the balance between excitatory glutamater-
gic projections from the motor cortex to the STN and
inhibitory projections from GPe to the STN (Figure 1(a)),
while in PD patients such balancemay be disrupted, resulting
in an overactivity of the STN (Figure 1(b)). Recently, an
experimental study [41] showed that in amodel of PD inmice
the overactivity of glutamatergic projections from the motor
cortex to the STN may give rise not only to a pathologically
increased activation of postsynaptic NMDA receptors in the
STN (resulting in a pathological overactivity of the STN), but
also to an increased expression of GABAA receptors in the
membrane of STN neurons.
On the basis of the experimental studies mentioned
above [39–41], we can hypothesize that in PD the decreased
GABAergic inhibition exerted by the external globus pallidus
(GPe) through the indirect pathway on the glutamatergic
neurons of the STN and the GABAergic neurons of the GPi
and SNrmay result in compensatory upregulation of GABAA
receptors in various deafferented brain structures, namely, the
STN, GPi, and SNr (Figure 2(b)).
On the basis of such experimental studies [39–41], we
might also speculate that, as compared to PD patients who
after assuming zolpidem do not improve their motor symp-
toms or do experience drowsiness, in patients with PD who
after the administration of zolpidem show an improvement of
Parkinsonian motor symptoms and do not show remarkable
drowsiness, amoremarked upregulation ofGABAA receptors
may occur in some critical structures overactive in PD (GPi,
SNr, and STN). Accordingly, it might be hypothesized that
in the subset of patients who resulted in being responders
to zolpidem with a hypothetical more marked upregulation
of GABAA receptors in such overactive structures (GPi, SNr,
and STN), zolpidem might bind to a relatively greater extent
to these specific subcortical structures (GPi, SNr, and STN),
at variance with other PD patients or normal subjects in
whom zolpidem might preferentially bind to other brain
structures (different from GPi, SNr, and STN) involved in
sleep induction, thus inducing drowsiness. In the subset of
PD patients responders to zolpidem, we might hypothesize
that the relatively greater binding of zolpidem (Figure 1(c))
to such specific subcortical overactive structures in PD (GPi,
SNr, and STN)may finally give rise to an increased inhibition
of the two inhibitory output GABAergic structures of the
basal ganglia (GPi and SNr), resulting in increased activity of
specific thalamic nuclei and of specific cortical areas (such as
the supplementarymotor area). According to our hypothesis,
such increased activity of specific cortical areas resulting
from a more marked upregulation of GABAA receptors in
critical subcortical structures overactive in PD (GPi, SNr,
and STN) might account for both the beneficial effects of
zolpidem on Parkinsonian motor symptoms and the absence
(or minimal degree) of drowsiness observed in a subset of
PD patients (mostly with a good response to zolpidem), as
compared to other PD patients who are nonresponders to
zolpidem or show drowsiness even after low doses of this
drug.
Accordingly, wemight also speculate that, as compared to
PDpatients in early stages presentingwithmild Parkinsonian
motor symptoms, PD patients in more advanced disease
stages and presenting with severe Parkinsonian motor symp-
toms might on average tolerate higher dosages of zolpidem,
possibly because in advanced PD there might be a greater
deafferentation of critical subcortical structures overactive
in PD (GPi, SNr, and STN), in whom a more marked































Figure 2: Schematic representation of the activity of the cortical-basal ganglia circuits in normal subjects (a) and in patients with Parkinson’s
disease/Parkinsonism (b), resulting in a possible compensatory upregulation of GABAA receptors in various nuclei (STN, GPi, and SNr),
which are overactive in PD. In PD, the underactivity of GABAergic neurons of the putamen and caudate projecting to GPi and SNr through
the direct (D) pathway (b) may result in compensatory upregulation of GABAA receptors [39] in deafferented brain structures, namely, the
GPi and SNr (b). Similarly, we can hypothesize that in PD the decreased GABAergic inhibition exerted by the external globus pallidus (GPe)
through the indirect (I) pathway on the glutamatergic neurons of the STN and the GABAergic neurons of the GPi and SNr (b) may result in
compensatory upregulation of GABAA receptors in such deafferented brain structures (STN, GPi, and SNr). Such compensatory upregulation
of GABAA receptors in deafferented brain structures (STN, GPi, and SNr) could bemoremarked in PD patients who, after the administration
of zolpidem, show more evident beneficial effects on Parkinsonian motor symptoms and show no or minimal drowsiness. White arrows =
excitatory connections; black arrows = inhibitory connections.
5. Potential Beneficial Effects of Zolpidem,
Possibly through a Positive Allosteric
Modulation of GABAA Receptors Containing
the 𝛼1 Subunit, in Neurological Disorders
other than PD
In the last two decades, following the initial serendipitous
observation in PD [18], various reports have suggested that
the administration of zolpidem may induce beneficial effects
in a variety of neurological disorders other than PD, such
as other Parkinsonian syndromes (as further briefly sum-
marized below) and other neurological conditions associated
with dysfunction of the basal ganglia, including dystonia [42–
49] and tardive dyskinesia and acathisia [50]. In addition,
it was reported that zolpidem may induce a symptomatic
improvement in a variety of other conditions associated
with motor dysfunction, such as restless leg syndrome [51],
postanoxic spasticity [52], spinocerebellar ataxia [53], and
central pontine myelinolysis [54]. Furthermore, it has been
observed that the administration of zolpidem may induce
beneficial effects in some patients with stroke [55] and in a
subset of patients with disorders of consciousness [56–62].
Beneficial effects of zolpidemwere reported in a variety of
Parkinsonian syndromes other than PD, including Progres-
sive Supranuclear Palsy [31, 63–66] and X-Linked Dystonia
Parkinsonism [67, 68]. Although the beneficial effects on
zolpidem on motor symptoms of Progressive Supranuclear
Palsy (PSP) are not the main focus of this review, we will
briefly mention some observations suggesting the possibility
to improvemotor symptoms (akinesia, rigidity, voluntary eye
movements, dysarthria, and dysphagia) in patients with PSP,
who are usually poorly responsive to levodopa and other anti-
Parkinsonian drugs.
In the 90s, Daniele and coworkers observed a 58-year-old
man affected by PSPwith 5-year clinical history [31], whowas
given a 10mg oral dose of an immediate-release formulation
of zolpidem in the morning in the attempt to assess possible
beneficial effects of zolpidem on motor symptoms of PSP, in
analogy with the motor improvement previously observed in
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PD patients [18]. After the assumption of such single dose of
zolpidem, this patient showed for some hours a remarkable
improvement of several motor symptoms of PSP (akinesia,
rigidity, voluntary eye movements, and dysarthria), in the
absence of drowsiness. Following such observation, a pilot
study (with a double-blind, placebo-controlled, crossover
design) was carried out in 10 patients with a clinical diagnosis
of probable PSP [31], who received in four separate trials
in randomized order two single oral doses of zolpidem
(5 and 10mg), a single dose of levodopa (250mg) plus
carbidopa (25mg), and placebo. After withholding of all anti-
Parkinsonian medication 12 hours before motor assessment,
PSP patients were examined bymeans of theUPDRS-III scale
before (baseline) and one hour after the administration of the
active drug or placebo. A positive response in each individual
patient was defined as a decrease of more than 20% of the
UPDRS-III score at baseline. In this pilot study, the adminis-
tration of a single 5mg dose of immediate-release zolpidem,
unlike placebo, induced a slight but significant improvement
of motor symptoms of PSP as assessed by UPDRS-III scale
(namely, a 6.5% mean reduction of UPDRS-III scores from
baseline). After the administration of zolpidem, two out of
10 PSP patients showed a decrease of more than 20% of
the UPDRS-III score at baseline and an improvement of
voluntary saccadic eyemovementswas observed in 4 out of 10
patients. In PSP patients responding to zolpidem, the motor
improvement appeared 40–60 minutes after the administra-
tion of zolpidem, lasted about 2 hours, and mainly involved
rigidity, akinesia/bradykinesia, and voluntary saccadic eye
movements. In this pilot study, the only adverse effects
observed after the administration of immediate-release zolpi-
dem were drowsiness and increased postural instability,
which were more marked after a single 10mg dose of
zolpidem. Subsequent observations with immediate-release
and controlled-released formulations of zolpidem [63–66]
confirmed that in patients with PSP the administration of
zolpidem (both in single doses and chronically) may induce
remarkable beneficial effects on most motor symptoms of
PSP (akinesia, rigidity, voluntary eye movements, dysarthria,
and dysphagia), which in some patients becamemore evident
after the administration of controlled-released formulations
of zolpidem, with a possible delay of some weeks between the
start of treatment with controlled-released zolpidem and the
appearance of an improvement of motor symptoms of PSP.
In 2001, Farver and Khan [34] described a 34-year-old
man affected by schizoaffective disorder and antipsychotic-
induced Parkinsonism with tremors of the hands for numer-
ous years, unresponsive to various medications (benztropine,
biperiden, amantadine, and propranolol). Zolpidem was
administered to this patient (10mg four times daily) and the
tremor significantly decreased. Moreover, after one month
of chronic treatment with zolpidem, the patient showed a
dramatic improvement of Parkinsonian motor symptoms,
with a score decrease from 29 at baseline to 9 on the motor
examination part of the UPDRS (UPDRS-III). After a 4-
month period of chronic treatment of the Parkinsonian
motor symptoms of this patient with zolpidem (at a dosage
of 10mg q.i.d.), he showed a worsening of psychotic symp-
toms (delusions, hallucinations). Accordingly, clozapine was
started and zolpidem was discontinued, due to excessive
sedation induced by the administration of clozapine together
with zolpidem. After the discontinuation of chronic treat-
ment with zolpidem, tremor reemerged in this patient. In the
attempt to improve again his Parkinsonian motor symptoms,
chronic treatment with zolpidem was reinitiated at a lower
dosage (5mg q.i.d.), with stabilization of Parkinsonianmotor
symptoms over a 2-year period. This report suggests the
potential benefits of the chronic administration of zolpidem
in patients affected by Parkinsonism induced by neuroleptics.
In 2006, at the 10th International Congress of Parkin-
son’s Disease and Movement Disorders organized by the
Movement Disorders Society, Kawashima and coworkers
[69] reported a 70-year-old woman with a diagnosis of
Parkinsonism, presenting with resting tremor, bradyki-
nesia, and rigidity. This patient was treated with lev-
odopa/carbidopa, with unsatisfactory results, and underwent
cardiac 123I-metaiodobenzylguanidine scintigraphy, which
showed decreased uptake. Over the subsequent two years,
Parkinsonian motor symptoms gradually progressed and at
the age of 72 years she could not speak, eat, and walk. Fifteen
minutes after the administration of a single 5mg dose of
zolpidem for insomnia, her rigidity and akinesia dramatically
improved for about four hours and she could speak clearly, eat
foods, and take several steps with bilateral assistance. After
the administration of a single 5mg dose of zolpidem, the total
score obtained on the motor examination part of the UPDRS
(UPDRS-III) decreased from 78 at baseline to 56.The authors
suggested that, in a subgroup of patients with Parkinsonism
with poor response to levodopa, the administration of zolpi-
dem (even in low doses) may induce remarkable beneficial
effects on Parkinsonian motor symptoms.
X-Linked Dystonia Parkinsonism (XDP), known oth-
erwise as Lubag, is an X-Linked neurological syndrome
afflicting male adults in the Philippines [68], clinically char-
acterised by dystonia and Parkinsonism, poorly responsive
to pharmacological treatment. XDP is associated with muta-
tions in two genes, the /DYT3/ gene and the /TAF1/ (TATA
binding protein-associated factor-1) gene. Dystonia usually
starts focally in the lower limbs or oromandibular region and
may then spread to become generalized, while Parkinsonism
usually presents in later in the disease course, usually in
combination with dystonia. It has been reported that the
administration of a single 10mgoral dose of zolpidem in three
patients affected by XDP [67] induced after 15–45 minutes
in all three patients a dramatic improvement of dystonia
(100%, 32%, and 31% improvement on the Burke-Fahn-
Marsden dystonia score, resp.) and a dramatic improvement
of Parkinsonism (bradykinesia and rigidity) in 2 out of
3 patients (with 40%, 34%, and 0% improvement on the
UPDRS-III scale, resp.). All three patients affected by XDP
were treated chronically with zolpidem [67]. Patient 1, with
a slow titration of the daily dose of zolpidem and with
caffeine intake, adapted to sedation induced by zolpidem
and was treated chronically with very high daily dosages of
zolpidem (10mg every 2 hours). On follow-up, one year after
starting the chronic treatment with zolpidem, in patient 1,
efficacy on motor symptoms of XDP was still maintained.
Patient 2 did not tolerate daily doses of zolpidem higher
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than 20mg but showed beneficial effects onmotor symptoms
of XDP after chronic treatment with a 20mg daily dose of
zolpidem (10mg b.i.d.). Six months after starting the chronic
treatment with zolpidem, patient 2 developed diarrhea and
discontinued zolpidem, with subsequent disappearance of
diarrhea. In patient 3, a chronic treatment with zolpidem had
to be discontinued after 2months, only due to financial straits
of this patient. Since patient 3 was unemployed, a benefactor
gave him 120 tablets of zolpidem, which he stretched out
by taking only one 10mg tablet b.i.d. In this patient, the
administration of zolpidem 10mg b.i.d. induced beneficial
effects with no side effects, but he ran out of zolpidem tablets
after 2 months of chronic treatment with zolpidem. In a
review paper on XDP [68], it has been pointed out that
zolpidem was the only drug showing remarkable beneficial
effects on disabling motor symptoms of patients affected by
XDP.
As to the mechanisms underlying the clinical improve-
ment observed after the administration of zolpidem in var-
ious neurological disorders other than movement disorders
(including Parkinson’s disease and Parkinsonian syndromes),
although suchmechanisms are still unclear, it seems plausible
to us that they might be related to the selective action of
zolpidem on GABAA receptors containing the 𝛼1 subunit,
resulting in enhanced activity of specific GABAergic circuits
across various brain structures. This general hypothesis is
supported by a recent experimental study on ischaemic stroke
inmice, suggesting that zolpidemmay improve recovery after
stroke in mice by enhancing phasic GABAergic inhibition
during the repair phase of stroke [70], which can be asso-
ciated with an increased number of 𝛼1 receptor subunit-
containing GABAergic synapses in the peri-infarct cerebral
cortex.
Currently available evidence [71–73] suggests that in
patients with brain damage due to stroke or associated with
various pathologies resulting in disorders of consciousness
the likelihood of beneficial effects of zolpidem seems to
be remarkably lower, unfortunately, as compared with the
likelihood of a motor improvement in PD patients. In
our view, in order to give a possible explanation for such
relatively low likelihood of beneficial effects of zolpidem in
patients affected by stroke or disorders of consciousness, we
might hypothesize that in such neurological conditions the
distribution of damage across different brain structures is
much less predictable than in patients with PD, in whom the
likelihood of beneficial effects of zolpidem seems accordingly
to be relatively higher, consistently with the hypothesis
of a selective action of zolpidem on GABAA receptors of
various subcortical structures (GPi, SNr, and STN), which
are overactive in PD. In other words, in stroke or disorders
of consciousness a poorly predictable distribution of damage
across different brain structures results in high individual
variability in the patterns of brain damage across different
patients. Accordingly, only in a (possibly relatively small)
subset of patients with stroke or disorders of conscious-
ness, a positive allosteric modulation of GABAA receptors
induced by the administration of zolpidem may give rise to
a positive allosteric modulation of GABAergic synapses in
specific neuronal networks, which may result in a clinical
improvement in such subset of patients. This hypothesis
might account for those observations reporting that the
proportion of brain-damaged patients with disorders of con-
sciousness who improve after the administration of zolpidem
might be relatively low in placebo-controlled and open-label
trials carried out on a relatively higher number of subjects
[71–73].
6. Concluding Remarks and Perspectives
Various studies and observations, although still preliminary
and sometimes published only in abstract form, consistently
suggest that zolpidem may induce beneficial (and often
clinically remarkable) effects in the treatment of motor
symptoms associated with a variety of movement disorders
[35], including PD and other Parkinsonian syndromes.
As to PD, a potential role of zolpidem in the treatment
of this disabling disorder is suggested by the following
considerations: (a) a number of clinical observations pro-
vided some clear-cut, although preliminary, evidence that
the oral administration of zolpidemmay remarkably improve
most motor symptoms of PD, even after a single dose of
zolpidem, as may be observed only with the most powerful
anti-Parkinsonian drugs (levodopa and apomorphine); (b)
in patients with PD, unlike most anti-Parkinsonian drugs,
zolpidem may also have antidyskinetic effects, which may be
very helpful in patients with advanced PD, who experience
dyskinesias and other symptoms associated with long-term
levodopa treatment; (c) in patients with advanced PD, who
become usually poorly responsive to current options of
pharmacological treatment and inwhom alternative pharma-
cological approaches aremore urgently needed, the beneficial
effects of zolpidem on Parkinsonian motor symptoms seem
to be more remarkable and a lower incidence of side effects
of zolpidem (such as drowsiness) may be observed with the
standard 10mg dose of zolpidem used for insomnia.
It remains to be ascertained whether in PD patients
the possible beneficial effect of zolpidem on Parkinsonian
motor symptoms may decrease after a certain period of
treatment with zolpidem, possibly due to disease progression
or due to the possible development of tolerance after the
chronic administration of zolpidem. The scanty evidence
available so far suggests that, at least in some individual PD
patients, the chronic administration of zolpidem might have
persistent beneficial effects for several months [21] or even
for years, namely, more than 3 years [19] or up to 5 years
[18]. Interestingly, in some PD patients the doses of zolpidem
had not been substantially increased over more than 3 years
of chronic administration [19] or had not been increased
at all up to 5 years of chronic administration of zolpidem
[18]. Long-term clinical trials are needed to clarify whether
in PD patients the possible beneficial effects of zolpidem on
Parkinsonian motor symptoms may decrease after a certain
period of chronic treatment with zolpidem and to clarify
whether specific clinical or pathophysiological features of
PD patients might predict the occurrence over time of a
decrease of beneficial effects of zolpidem on Parkinsonian
motor symptoms.
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The safety of a long-term treatment with zolpidem in
patients with PD has been recently questioned by two recent
retrospective observational studies, which analyzed a large
Taiwan National Health Insurance database [74, 75]. These
studies suggested that the overall incidence of PD was
significantly greater among a group of subjects with a history
of assumption of zolpidem for more than 3 months as sleep-
inducer, as compared to a group of subjects without a history
of assumption of zolpidem [74, 75]. In the first study [74],
the group of subjects who received zolpidem had a higher
cumulative rate of PD than the group of subjects who did
not receive zolpidem during a 5-year follow-up period, while
in the second study [75] after 5 years of observation the
incidence of PD did not differ between the two groups. Such
two studies, which according to their authors have various
limitations, suggested the hypothesis that the assumption of
zolpidem over more than 3 months may increase the risk for
PD. Interestingly, some experimental studies had suggested
that zolpidem may have neuroprotective effects, including in
vitro and in vivo antioxidant activity [76–78] and protective
effects against hypoxic stress [78]. It has been pointed out
[79] that no plausible mechanism was proposed for the
hypothetical relationship between the prolonged assumption
of zolpidem and an increased risk for PD. An alternative and
perhaps more parsimonious explanation for the findings of
such two retrospective studies has been recently proposed
by Andrade [79], who suggested that subjects with persistent
sleep disturbances (and therefore assuming zolpidem for
more than 3 months) are more likely to develop PD later,
since it has been established that in patients who develop PD
sleep disorders may antedate the onset of motor symptoms
by several years [80]. According to this latter view, persistent
sleep disturbances and the subsequent prolonged use of
zolpidem may have some predictive value, as persistent
sleep disturbances (requiring a prolonged use of zolpidem)
in a subgroup of subjects may simply represent very early
nonmotor symptoms of PD. Although according to this
perspective the prolonged assumption of zolpidem per se
would not play any significant role as a risk factor for PD,
further epidemiological studies are needed in order to draw
reliable conclusions about this potential safety issue related to
a long-term treatment with zolpidem.
In conclusion, a number of questions and issues need to
be faced at present. Controlled randomized clinical trials are
certainly needed in order to confirm the efficacy of zolpidem
in treating (possibly most) motor symptoms of PD patients,
to investigate the safety and tolerability of zolpidem in PD
patients, to find the most appropriate daily dose range of
zolpidem that can be administered to PD patients (ideally,
following an individualized and slow titration, in order to
find the optimal daily dosage of zolpidem in each patient),
to understand which are the best strategies to minimize
the possible occurrence of daytime drowsiness as adverse
effect of zolpidem, to check whether in patients treated with
zolpidem plus levodopa (or other dopaminergic agents) it is
possible to reduce the daily dosage of levodopa (or of other
dopaminergic agents), and to identify potential features in
individual PD patients (according to clinical symptoms or
according to possible neurophysiological or neuroimaging
markers) that might ideally predict a good chronic response
to zolpidem in PD patients.
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[26] A. A. Kühn, A. Kupsch, G.-H. Schneider, and P. Brown, “Reduc-
tion in subthalamic 8–35 Hz oscillatory activity correlates with
clinical improvement in Parkinson’s disease,” European Journal
of Neuroscience, vol. 23, no. 7, pp. 1956–1960, 2006.
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[76] G. Garćıa-Santos, F. Herrera, V. Mart́ın et al., “Antioxidant
activity and neuroprotective effects of zolpidem and several
synthesis intermediates,” Free Radical Research, vol. 38, no. 12,
pp. 1289–1299, 2004.
[77] M. Bishnoi, K. Chopra, and S. K. Kulkarni, “Possible anti-
oxidant and neuroprotective mechanisms of zolpidem in atten-
uating typical anti-psychotic-induced orofacial dyskinesia—
a biochemical and neurochemical study,” Progress in Neuro-
Psychopharmacology and Biological Psychiatry, vol. 31, no. 5, pp.
1130–1138, 2007.
[78] A. Kumar and R. Goyal, “Possible GABAergic modulation in
the protective effect of zolpidem in acute hypoxic stress-induced
behavior alterations and oxidative damage,” Neurochemical
Research, vol. 33, no. 3, pp. 370–377, 2008.
[79] C. Andrade, “Zolpidem use as a predictor of Parkinson’s
disease,” Journal of Psychiatric Research, vol. 60, p. 187, 2015.
[80] A. Raggi, R. Bella, G. Pennisi, W. Neri, and R. Ferri, “Sleep
disorders in Parkinson’s disease: a narrative review of the
literature,” Reviews in the Neurosciences, vol. 24, no. 3, pp. 279–
291, 2013.
